Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Fresenius & SamChunDang Exclusive US & LATAM Licence for Aflibercept Biosimilar

Dec 20, 2024

On 20 December 2024, Fresenius Kabi announced that it had entered into a licensing agreement with SamChunDang Pharm (SCD) to exclusively commercialise South Korean developed SCD-411, biosimilar to Regeneron’s Eylea® (aflibercept), in the United States, Brazil, Argentina, Chile, Paraguay, Colombia, and Mexico.  SCD is responsible for the development, manufacture, and supply of SCD-411.

This licensing deal follows news in March this year that SCD entered an exclusive distribution agreement with an unnamed distributor to supply SCD-411 in the UK, Belgium, the Netherlands, Norway, Portugal, Sweden, Greece, Ireland, and Finland.   SCD-411 was also the subject of an exclusive distribution agreement reported in November 2023, between SCD and an unnamed distributor, for supply to Austria, Germany, Italy, Spain, and Switzerland.  SCD has licensed SCD411 to Apotex for the Canadian market.